Methylation of the androgen receptor promoter CpG island is associated with loss of androgen receptor expression in prostate cancer cells

David F. Jarrard, Hidefumi Kinoshita, Yan Shi, Carol Sandefur, Douglas Hoff, Lorraine F. Meisner, Chawnshang Chang, James G. Herman, William B Isaacs, Nadine Nassif

Research output: Contribution to journalArticle

Abstract

Androgen-independent metastatic prostate cancer is characterized by a heterogeneous loss of androgen receptor (AR) expression among tumor cells. In this study, we evaluate DNA hypermethylation as a potential transcriptional regulatory mechanism in AR-negative prostate cancer cell lines. Nucleotide sequence analysis demonstrates a ~1.5-kb CpG island in the AR gene that encompasses the transcription start site and exon 1. Using Southern blotting with methylation-sensitive restriction enzymes and methylation-specific PCR, we find aberrant methylation in the AR expression-negative cell lines Du145, DuPro, TSU-PR1, and PPC1. Incomplete methylation in the AR CpG island is also seen in normal female breast and ovarian tissues consistent with the inactivation of one X chromosome by hypermethylation. In contrast, prostate cancer cell lines LNCaP and PC3 express AR and are unmethylated. Normal prostate epithelial cell strains demonstrate no methylation. Exposure of AR- negative prostate cancer cell lines to 5-aza-2' deoxycylidine, a demethylating agent, induces the reexpression of AR RNA in DuPro and TSU- PR1. This reexpression is associated with a demethylation of this region. Prostate-specific antigen, an androgen-responsive gene, is also specifically induced in these lines after AR reexpression. Therefore, in vitro DNA methylation of the 5' CpG AR island may he associated with the loss of AR expression. Furthermore, our results demonstrate that treatment with demethylating agents may engender the reexpression and function of the androgen receptor in AR-negative cell lines.

Original languageEnglish (US)
Pages (from-to)5310-5314
Number of pages5
JournalCancer Research
Volume58
Issue number23
StatePublished - Dec 1 1998

Fingerprint

CpG Islands
Androgen Receptors
Methylation
Prostatic Neoplasms
Cell Line
Androgens
X Chromosome Inactivation
Transcription Initiation Site
DNA Methylation
Prostate-Specific Antigen
Southern Blotting
Islands
Genes
Sequence Analysis
Prostate
Exons
Breast

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Jarrard, D. F., Kinoshita, H., Shi, Y., Sandefur, C., Hoff, D., Meisner, L. F., ... Nassif, N. (1998). Methylation of the androgen receptor promoter CpG island is associated with loss of androgen receptor expression in prostate cancer cells. Cancer Research, 58(23), 5310-5314.

Methylation of the androgen receptor promoter CpG island is associated with loss of androgen receptor expression in prostate cancer cells. / Jarrard, David F.; Kinoshita, Hidefumi; Shi, Yan; Sandefur, Carol; Hoff, Douglas; Meisner, Lorraine F.; Chang, Chawnshang; Herman, James G.; Isaacs, William B; Nassif, Nadine.

In: Cancer Research, Vol. 58, No. 23, 01.12.1998, p. 5310-5314.

Research output: Contribution to journalArticle

Jarrard, DF, Kinoshita, H, Shi, Y, Sandefur, C, Hoff, D, Meisner, LF, Chang, C, Herman, JG, Isaacs, WB & Nassif, N 1998, 'Methylation of the androgen receptor promoter CpG island is associated with loss of androgen receptor expression in prostate cancer cells', Cancer Research, vol. 58, no. 23, pp. 5310-5314.
Jarrard DF, Kinoshita H, Shi Y, Sandefur C, Hoff D, Meisner LF et al. Methylation of the androgen receptor promoter CpG island is associated with loss of androgen receptor expression in prostate cancer cells. Cancer Research. 1998 Dec 1;58(23):5310-5314.
Jarrard, David F. ; Kinoshita, Hidefumi ; Shi, Yan ; Sandefur, Carol ; Hoff, Douglas ; Meisner, Lorraine F. ; Chang, Chawnshang ; Herman, James G. ; Isaacs, William B ; Nassif, Nadine. / Methylation of the androgen receptor promoter CpG island is associated with loss of androgen receptor expression in prostate cancer cells. In: Cancer Research. 1998 ; Vol. 58, No. 23. pp. 5310-5314.
@article{6c0bcbf3cc134af884d9f1061a319a2a,
title = "Methylation of the androgen receptor promoter CpG island is associated with loss of androgen receptor expression in prostate cancer cells",
abstract = "Androgen-independent metastatic prostate cancer is characterized by a heterogeneous loss of androgen receptor (AR) expression among tumor cells. In this study, we evaluate DNA hypermethylation as a potential transcriptional regulatory mechanism in AR-negative prostate cancer cell lines. Nucleotide sequence analysis demonstrates a ~1.5-kb CpG island in the AR gene that encompasses the transcription start site and exon 1. Using Southern blotting with methylation-sensitive restriction enzymes and methylation-specific PCR, we find aberrant methylation in the AR expression-negative cell lines Du145, DuPro, TSU-PR1, and PPC1. Incomplete methylation in the AR CpG island is also seen in normal female breast and ovarian tissues consistent with the inactivation of one X chromosome by hypermethylation. In contrast, prostate cancer cell lines LNCaP and PC3 express AR and are unmethylated. Normal prostate epithelial cell strains demonstrate no methylation. Exposure of AR- negative prostate cancer cell lines to 5-aza-2' deoxycylidine, a demethylating agent, induces the reexpression of AR RNA in DuPro and TSU- PR1. This reexpression is associated with a demethylation of this region. Prostate-specific antigen, an androgen-responsive gene, is also specifically induced in these lines after AR reexpression. Therefore, in vitro DNA methylation of the 5' CpG AR island may he associated with the loss of AR expression. Furthermore, our results demonstrate that treatment with demethylating agents may engender the reexpression and function of the androgen receptor in AR-negative cell lines.",
author = "Jarrard, {David F.} and Hidefumi Kinoshita and Yan Shi and Carol Sandefur and Douglas Hoff and Meisner, {Lorraine F.} and Chawnshang Chang and Herman, {James G.} and Isaacs, {William B} and Nadine Nassif",
year = "1998",
month = "12",
day = "1",
language = "English (US)",
volume = "58",
pages = "5310--5314",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "23",

}

TY - JOUR

T1 - Methylation of the androgen receptor promoter CpG island is associated with loss of androgen receptor expression in prostate cancer cells

AU - Jarrard, David F.

AU - Kinoshita, Hidefumi

AU - Shi, Yan

AU - Sandefur, Carol

AU - Hoff, Douglas

AU - Meisner, Lorraine F.

AU - Chang, Chawnshang

AU - Herman, James G.

AU - Isaacs, William B

AU - Nassif, Nadine

PY - 1998/12/1

Y1 - 1998/12/1

N2 - Androgen-independent metastatic prostate cancer is characterized by a heterogeneous loss of androgen receptor (AR) expression among tumor cells. In this study, we evaluate DNA hypermethylation as a potential transcriptional regulatory mechanism in AR-negative prostate cancer cell lines. Nucleotide sequence analysis demonstrates a ~1.5-kb CpG island in the AR gene that encompasses the transcription start site and exon 1. Using Southern blotting with methylation-sensitive restriction enzymes and methylation-specific PCR, we find aberrant methylation in the AR expression-negative cell lines Du145, DuPro, TSU-PR1, and PPC1. Incomplete methylation in the AR CpG island is also seen in normal female breast and ovarian tissues consistent with the inactivation of one X chromosome by hypermethylation. In contrast, prostate cancer cell lines LNCaP and PC3 express AR and are unmethylated. Normal prostate epithelial cell strains demonstrate no methylation. Exposure of AR- negative prostate cancer cell lines to 5-aza-2' deoxycylidine, a demethylating agent, induces the reexpression of AR RNA in DuPro and TSU- PR1. This reexpression is associated with a demethylation of this region. Prostate-specific antigen, an androgen-responsive gene, is also specifically induced in these lines after AR reexpression. Therefore, in vitro DNA methylation of the 5' CpG AR island may he associated with the loss of AR expression. Furthermore, our results demonstrate that treatment with demethylating agents may engender the reexpression and function of the androgen receptor in AR-negative cell lines.

AB - Androgen-independent metastatic prostate cancer is characterized by a heterogeneous loss of androgen receptor (AR) expression among tumor cells. In this study, we evaluate DNA hypermethylation as a potential transcriptional regulatory mechanism in AR-negative prostate cancer cell lines. Nucleotide sequence analysis demonstrates a ~1.5-kb CpG island in the AR gene that encompasses the transcription start site and exon 1. Using Southern blotting with methylation-sensitive restriction enzymes and methylation-specific PCR, we find aberrant methylation in the AR expression-negative cell lines Du145, DuPro, TSU-PR1, and PPC1. Incomplete methylation in the AR CpG island is also seen in normal female breast and ovarian tissues consistent with the inactivation of one X chromosome by hypermethylation. In contrast, prostate cancer cell lines LNCaP and PC3 express AR and are unmethylated. Normal prostate epithelial cell strains demonstrate no methylation. Exposure of AR- negative prostate cancer cell lines to 5-aza-2' deoxycylidine, a demethylating agent, induces the reexpression of AR RNA in DuPro and TSU- PR1. This reexpression is associated with a demethylation of this region. Prostate-specific antigen, an androgen-responsive gene, is also specifically induced in these lines after AR reexpression. Therefore, in vitro DNA methylation of the 5' CpG AR island may he associated with the loss of AR expression. Furthermore, our results demonstrate that treatment with demethylating agents may engender the reexpression and function of the androgen receptor in AR-negative cell lines.

UR - http://www.scopus.com/inward/record.url?scp=0032403081&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032403081&partnerID=8YFLogxK

M3 - Article

C2 - 9850055

AN - SCOPUS:0032403081

VL - 58

SP - 5310

EP - 5314

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 23

ER -